{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T16:27:28Z","timestamp":1747326448463},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,1]]},"DOI":"10.7759\/cureus.14788","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T14:32:01Z","timestamp":1619879521000},"source":"Crossref","is-referenced-by-count":3,"title":["Comparison Between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Incidence of Lung Cancer: A Retrospective Study"],"prefix":"10.7759","author":[{"given":"Pardeep","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FNU","family":"Murlidhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliya","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Jahangir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dua","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Khizar","family":"Memon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidra","family":"Memon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Besham","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2019.05.003","article-title":"Blood pressure and the new ACC\/AHA hypertension guidelines","volume":"30","author":"Flack JM","year":"2020","unstructured":"Flack JM, Adekola B. Blood pressure and the new ACC\/AHA hypertension guidelines. Trends Cardiovasc Med. 2020, 30:160-4. 10.1016\/j.tcm.2019.05.003","journal-title":"Trends Cardiovasc Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002315","article-title":"US hypertension management guidelines: a review of the recent past and recommendations for the future","volume":"4","author":"Kovell LC","year":"2015","unstructured":"Kovell LC, Ahmed HM, Misra S, Whelton SP, Prokopowicz GP, Blumenthal RS, McEvoy JW. US hypertension management guidelines: a review of the recent past and recommendations for the future. J Am Heart Assoc. 2015, 4:e002315. 10.1161\/JAHA.115.002315","journal-title":"J Am Heart Assoc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/1470320320981321","article-title":"Effects of ACEI and ARB on COVID-19 patients: a meta-analysis","volume":"21","author":"Xue Y","year":"2020","unstructured":"Xue Y, Sun S, Cai J, et al.. Effects of ACEI and ARB on COVID-19 patients: a meta-analysis. J Renin Angiotensin Aldosterone Syst. 2020, 21:1470320320981321. 10.1177\/1470320320981321","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.2983","article-title":"Lung cancer incidence in never smokers","volume":"25","author":"Wakelee HA","year":"2007","unstructured":"Wakelee HA, Chang ET, Gomez SL, et al.. Lung cancer incidence in never smokers. J Clin Oncol. 2007, 25:472-8. 10.1200\/JCO.2006.07.2983","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4209","article-title":"Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study","volume":"363","author":"Hicks BM","year":"2018","unstructured":"Hicks BM, Filion KB, Yin H, Sakr L, Udell JA, Azoulay L. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ. 2018, 363:k4209. 10.1136\/bmj.k4209","journal-title":"BMJ"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030747","article-title":"Association between angiotensin-converting enzyme inhibitors and lung cancer-A nationwide, population-based, propensity score-matched cohort study","volume":"12","author":"Lin SY","year":"2020","unstructured":"Lin SY, Lin CL, Lin CC, et al.. Association between angiotensin-converting enzyme inhibitors and lung cancer-A nationwide, population-based, propensity score-matched cohort study. Cancers (Basel). 2020, 12:747. 10.3390\/cancers12030747","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.006687","article-title":"Use of ACE (angiotensin-converting enzyme) inhibitors and risk of lung cancer: a nationwide nested case-control study","volume":"14","author":"Kristensen KB","year":"2021","unstructured":"Kristensen KB, Hicks B, Azoulay L, Potteg\u00e5rd A. Use of ACE (angiotensin-converting enzyme) inhibitors and risk of lung cancer: a nationwide nested case-control study. Circ Cardiovasc Qual Outcomes. 2021, 14:e006687. 10.1161\/CIRCOUTCOMES.120.006687","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials","volume":"12","author":"Bangalore S","year":"2011","unstructured":"Bangalore S, Kumar S, Kjeldsen SE, et al.. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011, 12:65-82. 10.1016\/S1470-2045(10)70260-6","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328344a7de","article-title":"Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals","volume":"29","year":"2011","unstructured":"Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 2011, 29.623-35. 10.1097\/HJH.0b013e328344a7de","journal-title":"J Hypertens"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/er.2003-0001","article-title":"Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation","volume":"24","author":"Carey RM","year":"2003","unstructured":"Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev. 2003, 24:261-71. 10.1210\/er.2003-0001","journal-title":"Endocr Rev"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1183\/09031936.93.06040576","article-title":"Kinins and respiratory tract diseases","volume":"6","author":"Trifilieff A","year":"1993","unstructured":"Trifilieff A, Da Silva A, Gies JP. Kinins and respiratory tract diseases. Eur Respir J. 1993, 6:576-87.","journal-title":"Eur Respir J"},{"key":"ref12","article-title":"The kinin system--bradykinin: biological effects and clinical implications. Multiple role of the kinin system--bradykinin","volume":"11","author":"Golias Ch","year":"2007","unstructured":"Golias Ch, Charalabopoulos A, Stagikas D, Charalabopoulos K, Batistatou A. The kinin system--bradykinin: biological effects and clinical implications. Multiple role of the kinin system--bradykinin. Hippokratia. 2007, 11:124-8.","journal-title":"Hippokratia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.87.318","article-title":"A potential role of bradykinin in angiogenesis and growth of S-180 mouse tumors","volume":"87","author":"Ishihara K","year":"2001","unstructured":"Ishihara K, Hayash I, Yamashina S, Majima M. A potential role of bradykinin in angiogenesis and growth of S-180 mouse tumors. Jpn J Pharmacol. 2001, 87:318-26. 10.1254\/jjp.87.318","journal-title":"Jpn J Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2174\/1381612033454171","article-title":"Bradykinin antagonists as anti-cancer agents","volume":"9","author":"Stewart JM","year":"2003","unstructured":"Stewart JM. Bradykinin antagonists as anti-cancer agents. Curr Pharm Des. 2003, 9:2036-42. 10.2174\/1381612033454171","journal-title":"Curr Pharm Des"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03228-0","article-title":"Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?","volume":"352","author":"Lever AF","year":"1998","unstructured":"Lever AF, Hole DJ, Gillis CR, et al.. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?. Lancet. 1998, 352:179-84. 10.1016\/S0140-6736(98)03228-0","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/57751-comparison-between-angiotensin-converting-enzyme-inhibitors-and-angiotensin-receptor-blockers-for-incidence-of-lung-cancer-a-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:32:46Z","timestamp":1707507166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/57751-comparison-between-angiotensin-converting-enzyme-inhibitors-and-angiotensin-receptor-blockers-for-incidence-of-lung-cancer-a-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.14788","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,1]]}}}